Yun Seong-Hoon, Roh Mee-Sook, Jeong Jin-Sook, Park Joo-In
Department of Biochemistry, Dong-A University College of Medicine, 32 Daesingongwon-ro, Seo-Gu, Busan 49201, Republic of Korea.
Department of Pathology, Dong-A University College of Medicine, 32 Daesingongwon-ro, Seo-Gu, Busan 49201, Republic of Korea.
Ann Diagn Pathol. 2018 Apr;33:11-16. doi: 10.1016/j.anndiagpath.2017.11.007. Epub 2017 Nov 10.
Peroxisome proliferator-activated receptor γ (PPARγ) and PPARγ coactivator-1α (PGC-1α) expression levels are correlated with clinical outcome in breast cancer. However, the potential biological and clinical significance of PPARγ and PGC-1α in colorectal cancer remains unknown. Here we investigated PPARγ and PGC-1α expression in colorectal cancer, and the associations of these expression levels with clinicopathological features. We also evaluated the roles of PPARγ and PGC-1α as prognostic factors in colorectal cancer. We performed immunohistochemical analysis to investigate PPARγ and PGC-1α expression in human colorectal cancer tissues and adjacent normal tissues from 108 primary colorectal cancer patients. We then examined how these expression levels correlated with clinicopathological features. Using the Kaplan-Meier method, we evaluated 3-year disease-free survival (DFS) and overall survival (OS) in patients with tumors expressing different levels of PPARγ and PGC-1α. Our results revealed that PPARγ expression was not significantly correlated with age at surgery, gender, differentiation, depth of infiltration, relapse, or TNM stage. Additionally, PGC-1α expression was not significantly correlated with age at surgery, differentiation, depth of infiltration, relapse, or TNM stage. However, PGC-1α expression was significantly correlated with nodal metastasis (p=0.020). Survival analysis demonstrated reduced OS in the PGC-1α-positive group compared to the PGC-1α-negative group (p=0.03). Our present findings suggest that PGC-1α may be useful for predicting nodal metastasis, and may represent a biomarker for poor prognosis in colorectal cancer.
过氧化物酶体增殖物激活受体γ（PPARγ）和PPARγ共激活因子-1α（PGC-1α）的表达水平与乳腺癌的临床结局相关。然而，PPARγ和PGC-1α在结直肠癌中的潜在生物学和临床意义仍不清楚。在此，我们研究了结直肠癌中PPARγ和PGC-1α的表达，以及这些表达水平与临床病理特征的关联。我们还评估了PPARγ和PGC-1α作为结直肠癌预后因素的作用。我们对108例原发性结直肠癌患者的人类结直肠癌组织及相邻正常组织进行免疫组化分析，以研究PPARγ和PGC-1α的表达。然后，我们检查了这些表达水平与临床病理特征的相关性。使用Kaplan-Meier方法，我们评估了PPARγ和PGC-1α表达水平不同的肿瘤患者的3年无病生存率（DFS）和总生存率（OS）。我们的结果显示，PPARγ表达与手术年龄、性别、分化程度、浸润深度、复发或TNM分期无显著相关性。此外，PGC-1α表达与手术年龄、分化程度、浸润深度、复发或TNM分期也无显著相关性。然而，PGC-1α表达与淋巴结转移显著相关（p=0.020）。生存分析表明，与PGC-1α阴性组相比，PGC-1α阳性组的OS降低（p=0.03）。我们目前的研究结果表明，PGC-1α可能有助于预测淋巴结转移，并且可能代表结直肠癌预后不良的一个生物标志物。
